Photodiagnosis and Photodynamic Therapy
Volume 7, Issue 2 , Pages 76-85 , June 2010

Photodynamic applications in brain tumors: A comprehensive review of the literature

  • Sam Eljamel, MD, FRCS

      Affiliations

    • Corresponding Author InformationTel.: +44 1382 42 5712; fax: +44 1382 496202.
    web address

References 

  1. Stupp R. Malignant gliomas: ESMO clinical recommendations for diagnosis, treatment and follow up. Ann Oncol. 2007;18(Suppl. 2):60–70
  2. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncol. 2004;6(3):227–235
  3. Rich JN, Hans C, Jones B, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 2005;65:4051–4058
  4. Kleihues P, Burger PC, Cavenee WK, Glioblastoma . WHO classification: pathology and genetics of tumors of the nervous system. Lyon, France: International Agency for Research on Cancers; 1997;p. 16–24
  5. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res. 1997;3:523–530
  6. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25:2288–2294
  7. Amatya VJ, Naumann U, Weller M, Ohgaki H. TP53 promoter methylation in human gliomas. Acta Neuropathol. 2005;110:178–184
  8. Korkolopoulou P, Christodoulou P, Kouzelis K, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer. 1997;75:1269–1278
  9. Duerr EM, Rollbrocker B, Hayashi Y, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene. 1998;16:2259–2264
  10. Scott JN, Rewcastle NB, Brasher PM, et al. Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci. 1998;25:197–201
  11. Olsen JJ, Ryken T. Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J Neuro-Oncol. 2008;89:255–258
  12. Vecht CJ, Avezaat CJ, van Putten WL, Eijkenboom WM, Stefanko SZ. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry. 1990;53:466–471
  13. Curran WJ, Scott CB, Horton J, et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neuro-Oncol. 1992;12:219–227
  14. Prados MD, Gutin PH, Phillips TL, et al. Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int J Radiat Oncol Biol Phys. 1992;24:593–597
  15. Lai DM, Lin SM, Tu YK, Kao MC, Hung CC. Therapy for supratentorial malignant astrocytomas: survival and possible prognostic factors. J Formos Med Assoc. 1993;92:220–226
  16. Kreth FW, Warnke PC, Scheremet R, et al. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg. 1993;78:762–766
  17. Albert FK, Forsting M, Sartor K, Adams H-P, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and influence on regrowth and prognosis. Neurosurgery. 1994;34:45–61
  18. Nitta T, Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer. 1995;75:2727–2731
  19. Kiwit JC, Floeth FW, Bock WJ. Survival in malignant glioma: analysis of prognostic factors with special regard to cytoreductive surgery. Zentralbl Neurochir. 1996;57:76–88
  20. Barker FG, Prados MD, Chang SM, et al. Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg. 1996;84:442–448
  21. Kowalczuk A, Macdonald RL, Amidei C, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery. 1997;41:1028–1038
  22. Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999;52:371–379
  23. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–198
  24. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99:467–473
  25. Kurimoto M, Hayashi N, Kamiyama H, et al. Impact of neuronavigation and image-guided extensive resection for adult patients with supratentorial malignant astrocytomas: a single-institution retrospective study. Minim Invasive Neurosurg. 2004;47:278–283
  26. Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg. 2006;105:34–40
  27. Stark AM, Nabavi A, Mehdorn HM, Blomer U. Glioblastoma multiforme—report of 267 cases treated at a single institution. Surg Neurol. 2005;63:162–169
  28. Eljamel MS. Fluorescence image guided surgery of brain tumours: explained step by step. Photodiagn Photodyn Ther. 2008;5:260–263
  29. Eljamel MS. Brain PDD and PDT unlocking the mystery of malignant gliomas. Photodiagn Photodyn Ther. 2005;1:303–310
  30. Eljamel MS. Photodynamic assisted surgical resection and treatment of malignant brain tumours technique, technology and clinical application. Photodiagn Photodyn Ther. 2004;1:93–98
  31. Eljamel MS. New light on the brain: the role of photosensitising agents and laser light in the management of invasive intracranial tumours. Technol Cancer Res Treat. 2003;2(4):303–309
  32. Kanako S, Kondo M. Photodynamic medicine in malignant glioma—the reason why ALA induced PpIX is accumulated. In: Proceedings of the 7th international PDT symposium. Brixen, Italy. 2008;
  33. Phillips JB. Differences in sensitivity to mTHPC-mediated photodynamic therapy of neurons, glial cells and MCF7 cells in a 3-dimensional cell culture model. In: Proceedings of the 7th international PDT symposium. Brixen, Italy. 2008;
  34. Kaneko S. Recent advances in PDD and PDT for malignant brain tumors. APLS Proc. 2008;1–4
  35. Eljamel MS, Good man C, Moseley H. ALA and photofrin (R) fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med Sci. 2008;23:361–367
  36. Moseley H, McLean C, Hockaday S, Eljamel S. In vitro light distributions from intracranial PDT balloons. Photodiagn Photodyn Ther. 2007;4:213–220
  37. Zilidis G, Aziz F, Telara S, Eljamel MS. Fluorescence image-guided surgery and repetitive photodynamic therapy in brain metastatic malignant melanoma. Photodiagn Photodyn Ther. 2008;5:264–266
  38. Aziz F, Telara S, Moseley H, Goodman C, Manthri P, Eljamel MS. Photodynamic therapy adjuvant to surgery in metastatic carcinoma in brain. Photodiagn Photodyn Ther. 2009;6:227–230
  39. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence guided resection of glioblastoma multiforme by using 5-aminolevulenic acid induced porphyrins, a prospective study in 52 consecutive patients. J Neurosurg. 2000;93:1003–1013
  40. Stummer W, Pitchimeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401
  41. Pichlmeier U, Bink A, Schackert G, Stummer W. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro-Oncol. 2008;10:1025–1034
  42. Kaneko S. A current overview: photodynamic diagnosis and photodynamic therapy using ALA in neurosurgery. J Jpn Soc Laser Surg Med (JJSLSM). 2008;29:135–146
  43. Perria C, Capuzzo T, Cavagnaro G, et al. Fast attempts at the photodynamic treatment of human gliomas. J Neurosurg Sci. 1980;24:119–129
  44. Kostron H, Weiser G, Fritsch E, Grunert V. Photodynamic therapy of malignant brain tumors: clinical and neuropathological results. Photochem Photobiol. 1987;46:937–943
  45. Stylli SS, Kaye AH, MacGregor L, Howes M, Rajendra P. Photodynamic therapy of high grade glioma—long term survival. J Clin Neurosci. 2005;12:389–398
  46. Kostron H. Photodynamic applications in neurosurgery. In: Proceedings of the international photodynamic therapy (IPA). Seattle. 2009;
  47. Kanako S. Photodynamic therapy in high grade gliomas. In: Proceedings of the 7th international PDT symposium. Brixen, Italy. 2006;
  48. Paul M, Wilson B. Photodynamic therapy of brain tumors—a work in progress. Lasers Surg Med 38:384–389.
  49. Smith GCS, Pell JP. Hazardous journey Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327:1459–1461
  50. Muller P, Wilson B. A randomized two arm clinical trail of Photophrin PDT and standard therapy in high grade gliomas. Phase III trial. In: Proceedings of the 6th international PDT symposium. Brixen, Italy. 2006;
  51. Stepp H, Beck T, Pongratz T, et al. ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. J Environ Pathol Toxicol Oncol. 2007;26:157–164
  52. Kostron H, Fiegele T, Akatuna E. Combination of FOSCAN® mediated fluorescence guided resection and photodynamic treatment as new therapeutic concept for malignant brain tumors. Med Laser Appl. 2006;21:285–290
  53. Whelan H, Strivatsal S. The proverbial light at the end of the tunnel in brain-tumor treatment. SPIE. 2009;doi:10.1117/2.1200907.1670 http://spie.org/documents/Newsroom/Imported/1670/1670_3646_1_2009-07-08.pdf
  54. Schmidt MH, Meyer GA, Reichert KW, et al. Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors. J Neuro-Oncol. 2004;67:201–207
  55. Krishnamurthy S, Powers SK, Witmer P, Brown T. Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors. Lasers Surg Med. 2000;27:224–234

PII: S1572-1000(10)00028-1

doi: 10.1016/j.pdpdt.2010.02.002

Photodiagnosis and Photodynamic Therapy
Volume 7, Issue 2 , Pages 76-85 , June 2010

Article Tools

* Image Usage & Resolution